Our Company

AltPep is a biomedical startup based along Seattle’s Lake Union focused on developing early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These toxic oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes.

Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach.

Our lead programs aim to identify Alzheimer’s Disease and Parkinson’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with these diseases.